<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006373</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-12246</org_study_id>
    <secondary_id>MCC-12246</secondary_id>
    <secondary_id>MCC-IRB-5670</secondary_id>
    <secondary_id>SB-MCC-12246</secondary_id>
    <secondary_id>NCI-G00-1865</secondary_id>
    <nct_id>NCT00006373</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of Intensive-Dose Topotecan, Ifosfamide/Mesna and Etoposide (Vepesid)(TIME) Followed by Autologous Stem Cell Rescue in High Risk Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow&#xD;
      transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by&#xD;
      autologous bone marrow transplantation or peripheral stem cell transplantation in treating&#xD;
      patients who have non-Hodgkin's lymphoma or Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of intensive high dose chemotherapy consisting of topotecan,&#xD;
           ifosfamide, and etoposide followed by autologous bone marrow or peripheral blood stem&#xD;
           cell transplantation in terms of response rate, progression free survival, and overall&#xD;
           survival in patients with high risk non-Hodgkin's lymphoma or Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of high dose topotecan and etoposide in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the pharmacodynamics and toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the role of either an up or down regulation of DNA topoisomerase I or II&#xD;
           amount and/or activity in terms of clinical response and toxicity in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive intensive high dose chemotherapy consisting of ifosfamide IV over 2&#xD;
      hours followed by topotecan IV over 30 minutes on days -8 to -6 and etoposide IV continuously&#xD;
      over 24 hours on days -5 to -3. Patients undergo autologous bone marrow or peripheral blood&#xD;
      stem cell transplantation on day 0.&#xD;
&#xD;
      Patients are followed at 3, 6, and 12 months, annually until disease relapse, and then every&#xD;
      6 months until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival as defined as the time from date of enrollment to the time of recurrence</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>TIME</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topotecan, Ifosfamide, Mesna and Etoposide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3</description>
    <arm_group_label>TIME</arm_group_label>
    <other_name>vepesid(R)</other_name>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6</description>
    <arm_group_label>TIME</arm_group_label>
    <other_name>Ifex(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6</description>
    <arm_group_label>TIME</arm_group_label>
    <other_name>topotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
    <arm_group_label>TIME</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6</description>
    <arm_group_label>TIME</arm_group_label>
    <other_name>Mesnex(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-Hodgkin's lymphoma&#xD;
&#xD;
               -  No lymphoblastic lymphoma&#xD;
&#xD;
               -  Under 55 years of age:&#xD;
&#xD;
                    -  Intermediate and high grade or aggressive disease that has relapsed and/or&#xD;
                       failed at least 2 salvage chemotherapy regimens OR&#xD;
&#xD;
                    -  Failed to achieve complete response after first line induction chemotherapy&#xD;
                       and failed at least 1 salvage chemotherapy regimen&#xD;
&#xD;
                    -  Low grade or indolent disease that has relapsed or failed to achieve&#xD;
                       complete response after first line induction chemotherapy and failed more&#xD;
                       than 2 salvage chemotherapy regimens&#xD;
&#xD;
               -  55 years of age and over:&#xD;
&#xD;
                    -  Intermediate and high grade or aggressive disease that has relapsed and/or&#xD;
                       failed to achieve complete response after first line induction chemotherapy&#xD;
&#xD;
                    -  Low grade or indolent disease that has relapsed or failed to achieve&#xD;
                       complete response after first line induction chemotherapy OR&#xD;
&#xD;
          -  Histologically confirmed Hodgkin's lymphoma&#xD;
&#xD;
               -  Under 55 years of age:&#xD;
&#xD;
                    -  Received at least 2 prior salvage chemotherapy regimens&#xD;
&#xD;
               -  55 years of age and over:&#xD;
&#xD;
                    -  Stage III or IV disease that has relapsed or failed to achieve remission&#xD;
                       after combination induction chemotherapy&#xD;
&#xD;
                    -  Prior primary radiotherapy allowed if relapse is high risk (e.g., recurrence&#xD;
                       in radiation field, B symptoms, or liver or bone marrow involvement)&#xD;
&#xD;
          -  No active leptomeningeal involvement or severe symptomatic CNS disease&#xD;
&#xD;
               -  Prior CSF tumor involvement allowed if asymptomatic and no evidence of disease on&#xD;
                  lumbar puncture or no tumor involvement on MRI of the brain&#xD;
&#xD;
          -  Solid tumors and brain metastases allowed&#xD;
&#xD;
               -  No evidence of disease by MRI and physical exam following optimal prior surgery&#xD;
                  and/or radiotherapy AND&#xD;
&#xD;
               -  At least 3 months since prior radiotherapy NOTE: A new classification scheme for&#xD;
                  adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of&#xD;
                  &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,&#xD;
                  &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
                  terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 64&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL*&#xD;
&#xD;
          -  SGOT or SGPT no greater than 2.5 times normal*&#xD;
&#xD;
          -  No severe hepatic dysfunction NOTE: *Unless due to primary malignancy&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No severe cardiac dysfunction&#xD;
&#xD;
          -  Ejection fraction at least 50% by MUGA scan&#xD;
&#xD;
          -  Essential hypertension controlled by medication allowed&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 50% of normal OR&#xD;
&#xD;
          -  No symptomatic obstructive or restrictive disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No insulin dependent diabetes mellitus&#xD;
&#xD;
          -  No uncompensated major thyroid or adrenal dysfunction&#xD;
&#xD;
          -  No significant skin breakdown from tumor or other disease&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior doxorubicin or daunorubicin allowed if total dose no greater than 450 mg/m2&#xD;
&#xD;
          -  No prior topotecan&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent nitroglycerin preparations for angina pectoris&#xD;
&#xD;
          -  No concurrent antiarrhythmic drugs for major ventricular arrhythmias&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven C. Goldstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

